Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Why Novo Nordisk surged 14% on new weight-loss drug results
Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...
FiercePharma5d
Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...
Maker of weight-loss drugs to ask Trump to pause price negotiations: Report
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...
Why Eli Lilly Stock Topped the Market Today
Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...
Eli Lilly & Co’s Promising Growth: Accelerated Revenue and Drug Pipeline Advances
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...
Nasdaq8d
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (NYSE: LLY) Mounjaro skyrocketing over the past year. However, Eli Lilly ...